进展期胃癌术后同步放化疗32例的回顾分析

Postoperative Chemoradiotherapy for Advanced Gastric Cancer:an Analysis of 32 Cases

目的:评价进展期胃癌术后同步放化疗的疗效和不良反应。方法:收集胃癌根治术后行同步放化疗患者32例及单纯化疗患者31例的临床资料,分析两组患者的1年、2年和3年生存率,同时评价放化疗期间出现的不良反应。结果:术后同步放化疗组和单纯化疗组1年生存率分别为75.0%和64.5%,2年生存率分别为62.5%和45.2%,3年生存率分别为56.2%和25.8%,平均生存时间分别为33.2个月和20.6个月,差异具有统计学意义(P<0.05)。治疗期间两组患者血液学毒性及胃肠道毒性发生率的差异无统计学意义。结论:进展期胃癌患者术后同步放化疗较单纯化疗可提高1年、2年和3年生存率,延长中位生存时间,不良反应可耐受。

Objective： To investigate the treatment efficacy and toxic effects of postoperative chemoradiotherapy compared with postoperative chemotherapy alone in patients with advanced gastric cancer. Methods： A total of 63 patients were collected from our hospital from December 2004 to November 2007. 32 patients received chemoradiotherapy following radical resection, and 31 patients received chemotherapy alone following radical resection. The 1-, 2- and 3-yr survival rate were evaluated, as well as the hematological and gastrointestinal toxic effects, and hepatic and renal function. Results： The 1-, 2- and 3-yr survival rate of the chemoradiotherapy group was 75.1 %, 62.5% and 56.2%, respectively, as compared with 64.5%, 45.2% and 25.8% in the chemotherapy group. The mean survival time was 33.2 months compared with 20.6 months, respectively. There was significant difference between the two groups（P〈0.05）. There was no significant difference in Grade Ⅲ-Ⅳ hematological and gastrointestinal toxic effects between the two groups. Conclusion： Postoperative chemoradiotherapy of advanced gastric cancer improves the 1- , 2- and 3-yr survival rate and prolongs the mean survival time compared with postoperative chemotherapy alone. The toxic effects are tolerable.